Active Filter(s):
Details:
Afrezza (technosphere insulin) is a USFDA approved insulin receptor agonist which is being evaluated for the treatment of type 1 or type 2 diabetes in pediatric patients.
Lead Product(s): Technosphere Insulin,Degludec
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024